CSP1 is a potent and selective ComD1 receptor agonist, with an IC50 of 10.3 nM. CSP1 is a major variants of competence-stimulating peptide (CSP), and it can regulate genetic transformation of S. pneumonia by modulating quorum sensing (QS). CSP1 can act as an antibacterial agent.

4'-Hydroxy-3'-methylacetophenone, a phenolic volatile compound, is isolated from Hawaiian green coffee beans (Coffea Arabica L.). 4'-Hydroxy-3'-methylacetophenone has potent antioxidant activities. 4'-Hydroxy-3'-methylacetophenone also can be used to synthesize heterocyclic compounds which have antimycobacterial activity.

GSK147 (GSK-147) is an antimalarial compound that targets blood-stage activity of the Plasmodium falciparum and Plasmodium vivax parasites (Pf IC50=40 nM).

Diazolidinyl urea, a broad spectrum preservative, is a formaldehyde-releasing compound that releases formaldehyde through its decomposition. Diazolidinyl urea is effective against most contaminating microorganisms, especially Pseudomonas.

(1R)-α-Pinene is a volatile monoterpene with antimicrobial activities. (1R)-α-Pinene reduces Bacillus cereus population growth, and exhibits repellent effects.

HSGN-189 is a potent lipoteichoic acid (LTA) biosynthesis inhibitor, exhibits potent antibacterial activity against both MRSA and VRE strains with MICs of 1 ug/mL.

BPH-1358 free base (NSC50460 free base) is a potent human farnesyl diphosphate synthase (FPPS) and undecaprenyl diphosphate synthase (UPPS) inhibitor with IC50s of 1.8 μM and 110 nM, respectively, and is active against S. aureus in vitro (MIC ~250 ng/mL).

BPH-1358 mesylate (NSC50460 mesylate) is a potent human farnesyl diphosphate synthase (FPPS) and undecaprenyl diphosphate synthase (UPPS) inhibitor with IC50s of 1.8 μM and 110 nM, respectively. BPH-1358 mesylate is active against S. aureus in vitro (MIC ~250 ng/mL).

PAA-38 is a highly potent selective inhibitor targeting bacterial prolyl-tRNA synthetase (ProRS). PAA-38 againsts Pseudomonas aeruginosa ProRS (PaProRS) with a Kd value of 0.399 nM and an IC50 value of 4.97 nM. PAA-38 againsts human cytoplasmic ProRSs (HsProRS) with an IC50 value of 35.5 nM. PAA-38 demonstrates an in vitro antibacterial activity of minimum inhibitory concentration (MIC) = 4-8 μg/mL.

Temporin L is a potent antimicrobial peptide and is active against Gram-negative bacteria and yeast strains. Temporin L also has antiendotoxin properties.

JNJ-6640 is an inhibitor targeting mycobacterial PurF (the first enzyme in the de novo purine biosynthesis pathway) with potent anti-tuberculosis activity. JNJ-6640 exhibits bactericidal activity against Mycobacterium tuberculosis in vitro, with an MIC90 of 8.6 nM. JNJ-6640 disrupts de novo purine biosynthesis, inhibits M. tuberculosis DNA replication in vivo. JNJ-6640 exhibits anti-tuberculosis efficacy in acutely infected mice. JNJ-6640 can be used for the study of tuberculosis.

PYO12 is a 3-phenyl-4-phenoxypyrazole type antibacterial compound. PYO12 exhibits selective activity against Gram-positive bacteria with MIC for S. aureus, B. subtilis, S. pneumoniae, and MRSA of 1, 1, 1, and 4 μg/mL respectively. PYO12 has no activity against Gram-negative bacteria. PYO12 can significantly increase bacterial membrane permeability and significantly upregulate cell wall stress-related genes, possibly by binding to the C55-PP part of lipid II. PYO12 shows a concentration-dependent bactericidal effect, has low toxicity to mammalian cells, and does not cause hemolysis. PYO12 can be used to develop new antibiotics targeting bacterial cell wall synthesis.

MC-02479 is a novel cephalosporin. RWJ-54428 has good activity against most of the organisms tested, including methicillin-resistant staphylococci, E. faecalis, and penicillin-resistant pneumococci, and has moderate activity against E. faecium.

BC-1175 (CB-181963) is a novel cephalosporin and antibacterial agent. CB-181963 displays strong binding to altered PBP 2a. CB-181963 demonstrates marked efficacy against MRSA, Klebsiella pneumoniae, Streptococcus pneumoniae, and Escherichia coli.

BAYV-3522 is an orally effective cephalosporin. BAYV-3522 has antibacterial activity against Gram positive bacteria and some respiratory pathogens. BAYV-3522 can be used in the research of infectious conditions.

HMRZ-62 is an antibacterial agent. HMRZ-62 exhibits antibacterial activity against Methicillin-resistant Staphylococcus aureus (MRSA) and Vancomycin-resistant Enterococcus faecalis (VRE).

Pilabactam (ANT3310) is a broad-spectrum covalent Serine β-Lactamase inhibitor, with IC50 values ranging from 1 nM to 175 nM (a panel of Serine β-Lactamase). Pilabactam potentiates activity of β-lactam antibiotics against Carbapenem-Resistant Enterobacterales (CRE) and Acinetobacter baumannii (CRAB). Pilabactam can be used in the research of bacterial infection.

sCNH240 (Compound P1) is an oral active and selective Rv1625c/Cya activator. sCNH240 has significant anti-tuberculosis activity with a MIC90 of 1.24 μM for Mycobacterium tuberculosis (Mtb) H37Rv strain on cholesterol. sCNH240 can be used for tuberculosis treatment research.

8-Br-GTP (tetrasodium) (8-Bromoguanosine-5'-triphosphate (tetrasodium)) is a derivative of the energy substrate – GTP, for protein synthesis and gluconeogenesis. 8-Br-GTP (tetrasodium) inhibits the E. coli GTPase FtsZ with a Ki of 31.8 μM. 8-Br-GTP (tetrasodium) promotes the assembly of porcine brain microtubules.

L 652813 is a quaternary ammonium heterocyclic amino β-lactam compound. L 652813 exhibits inhibitory activity against a broad spectrum of aerobic and anaerobic bacteria in vitro. L 652813 also exhibits good antibacterial activity in a mouse experimental bacteremia model.

FK 089 is an antibacterial Agent. FK 089 can be used for the research of infection.

DV-7751A is a new Fluoroquinolone and antibacterial agent. DV-7751A inhibits the supercoiling activity of DNA gyrases. DV-7751A exhibits antimicrobial activity against Streptococcus pneumonae, Streptococcus pyogenes, and Peptostreptococcus spp. DV-7751A has a rapid bactericidal effect against S. aureus, Escherichia coli, and P. aeruginosa.

E3709 is an antibacterial agent. E3709 exhibits significant inhibitory activity against Gram-positive bacteria, including Staphylococcus aureus (MRSA), Enterococcus faecalis, streptococci, Clostridia, and diphtheroids. E3709 can be used for research related to Gram-positive bacterial infections.

DS21412020 is a fluoroquinolone antibacterial agent. DS21412020 inhibits bacterial DNA gyrase (GyrA) and topoisomerase IV, leading to DNA breaks. DS21412020 exhibits significant activity against Gram-positive bacteria such as Staphylococcus aureus (MIC = 0.006 μg/mL), Streptococcus pneumoniae (MIC = 0.05 μg/mL), and Methicillin)-resistant Staphylococcus aureus (MIC = 0.2 μg/mL), and Gram-negative bacteria such as Escherichia coli (MIC = 0.006 μg/mL) and Pseudomonas aeruginosa (MIC = 0.78 μg/mL). DS21412020 significantly reduces bacterial load in mouse pneumonia and MRSA infection models. DS21412020 can be used in the development of next-generation quinolone antibiotics.

ABT-255 hydrochloride is an orally active anti-bacterial agent. ABT-255 hydrochloride exhibits potent in vitro potency (MIC = 0.016-0.031 μg/mL) against drug-susceptible and Rifampin- or Ethambutol-resistant Mycobacterium tuberculosis. ABT-255 hydrochloride shows efficacy against S. aureus, S. pneumoniae and E. coli and reduces viable counts of drug-resistant Mycobacterium tuberculosis in CF-1 mice. ABT-255 hydrochloride can be used for the study of pulmonary tuberculosis.

AJI-9561 is a benzoxazole derivative produced by Streptomyces sp. AJI-9561 exhibits cytotoxicity and antibacterial activity. AJI-9561 inhibits the proliferation of Jurkat T cells and mouse P388 leukemia cells, with its IC50 being 0.88 and 1.63 μM respectively. AJI-9561 can be used for research on anti-cancer and antibacterial properties.

KY-9 is an antibacterial active compound.

FCE-20696 (hydrochloride) is an orally active immunomodulator. FCE-20696 (hydrochloride) also shows anti-inflammation and anti-infection effects. FCE-20696 (hydrochloride) can be used for the researches of infection, inflammation and immunology, such as adjuvant arthritis.

CP-74667 is a quinolone antibacterial agent. CP-74667 shows high activity against Xanthomonas maltophilia (MIC50 = 1 μg/mL), Staphylococcus spp. (MIC50 = 0.06-0.12 μg/mL) and enterococci (MIC50 = 0.5-4 μg/mL).

E 5065 is an orally active antibacterial agent. E 5065 exhibits potent in vitro activity against Gram-negative microorganisms, Gram-positive cocci, and anaerobes. E 5065 exhibits an MIC90 of 0.5 μg/mL against Clostridium spp. E 5065 provides protection against experimental infections caused by P. aeruginosa.